CAR T-cell therapy for secondary CNS DLBCL. Blood Adv 2021 Dec 28;5(24):5626-5630
Date
09/23/2021Pubmed ID
34551065Pubmed Central ID
PMC8714710DOI
10.1182/bloodadvances.2021005292Scopus ID
2-s2.0-85122300713 (requires institutional sign-in at Scopus site) 40 CitationsAbstract
Management of secondary central nervous system (SCNS) involvement in relapsed or refractory aggressive B-cell lymphomas remains an area of unmet medical need. We report a single-center retrospective analysis of 7 adult patients with SCNS lymphoma (SCNSL) who underwent chimeric antigen receptor (CAR) T-cell therapy for their refractory disease, and we describe the safety of whole brain radiation therapy (WBRT) as a bridging therapy. Six patients (85.7%) achieved a complete response at day 28, and 1 patient had progressive disease. The median progression-free survival was 83 days (range, 28-219 days), and median overall survival was 129 days (range, 32-219 days). Three patients died as a result of disease progression. Of the 5 patients who received WBRT as bridging therapy, 3 had no immune effector cell-associated neurotoxicity syndrome (ICANS), but 2 patients had grade 1 or grade 3 ICANS. No grade 4 ICANS was reported in this subset of patients. We conclude that SCNSL should not preclude patients from receiving CAR T-cell therapy as a treatment option because of concerns regarding ICANS, and bridging with WBRT is not associated with increased ICANS.
Author List
Ahmed G, Hamadani M, Shah NNAuthors
Mehdi H. Hamadani MD Professor in the Medicine department at Medical College of WisconsinNirav N. Shah MD Associate Professor in the Medicine department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
Central Nervous SystemHumans
Immunotherapy, Adoptive
Retrospective Studies